The acquisition of SignalPath's CTMS platform will allow Verily to strengthen and expand its existing clinical trial system and evidence generation platform called Baseline that is designed to speed up clinical study execution
Alphabet company Verily has agreed to acquire US-based clinical trial solutions provider SignalPath for an undisclosed sum.
Established in 2014, SignalPath has developed a clinical trial management system (CTMS) called SignalPath platform to enhance the ease, quality and efficacy of carrying out clinical research at study sites.
SignalPath’s platform minimises fragmentation by leveraging an advanced software architecture with a cloud-based platform, thereby allowing to enhance management of a study site’s clinical trials portfolio.
Its technology infrastructure provides novel approaches to partners, which are said to improve the costs, complexities and time associated with clinical trials.
The SignalPath CTMS is said to digitise protocols for clients, as well as helps to avoid significant impediment to utilisation and ensure quality of trial execution.
The SignalPath Research Consortium (SPARC) includes top clinical research sites selected for their people, processes and track record.
SignalPath co-founder and CEO Dr Brad Hirsch said: “Combining these capabilities with Verily’s clinical studies platforms business accelerates our ability to scale these solutions and make them available to a larger group of sites as well as provide entirely new opportunities to our network.”
The acquisition of SignalPath will allow Verily to strengthen and expand the company’s existing clinical trial system and evidence generation platform called Baseline.
The Baseline platform facilitates quicker clinical trial execution, enhanced data aggregation and analysis, flexible study options designed for decentralised and hybrid trials.
It also helps to gather real-world data such as that generated by novel sensors and biomarkers.
According to Verily, the Baseline community includes more than 500,000 individuals who are interested in taking part in clinical research.
Verily clinical studies platforms president Dr Amy Abernethy said: “Joining forces helps to accelerate and scale our shared vision, increase efficiency and lower costs in clinical trials, empower clinical research sites with world class technology, and ultimately bring medicines to patients faster.”
SignalPath employees will be included under Verily’s clinical research business, upon the completion of the deal.